US FDA fires most negotiators for pharma user fee talks, sources say

Mass layoffs at the FDA, including senior negotiators, have disrupted the process of reauthorizing user fee programs that fund the agency's drug review system. Experts warn that the loss of experienced staff jeopardizes preparations for the 2027 reauthorization, potentially giving the pharmaceutical industry an advantage in negotiations.